These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 11406256)

  • 21. Optimal FK 506 dosage in patients under primary immunosuppression following liver transplantation.
    Winkler M; Pichlmayr R; Neuhaus P; McMaster P; Calne R; Otto G; Williams R; Bismuth H; Groth C
    Transpl Int; 1994; 7 Suppl 1():S58-63. PubMed ID: 11271312
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tacrolimus (FK 506) for rescue of chronic rejection following orthotopic liver transplantation.
    Sher LS; Cosenza CA; Petrovic LM; Rojter S; Hoffman A; Lopez RR; Meehan M; Pan SH; Vierling J; Makowka L
    Transplant Proc; 1996 Apr; 28(2):1011-3. PubMed ID: 8623212
    [No Abstract]   [Full Text] [Related]  

  • 23. Low-dose tacrolimus (FK 506)-based immunosuppressive protocol in living donor renal transplantation.
    Kokado Y; Takahara S; Kyo M; Ichimaru N; Toki K; Wang JD; Okuyama A
    Transplant Proc; 1999; 31(1-2):1151-4. PubMed ID: 10083515
    [No Abstract]   [Full Text] [Related]  

  • 24. [Comparison between tacrolimus (FK 506) and cyclosporin in immunosuppressive therapy after liver transplantation].
    Arnold JC; Theilmann L
    Z Gastroenterol; 1995 Oct; 33(10):624-5. PubMed ID: 7502559
    [No Abstract]   [Full Text] [Related]  

  • 25. Renal function in primary liver transplant recipients receiving neoral (cyclosporine) versus prograf (tacrolimus).
    Van Buren D; Payne J; Geevarghese S; MacDonell R; Chapman W; Wright JK; Helderman JH; Richie R; Pinson CW
    Transplant Proc; 1998 Jun; 30(4):1401-2. PubMed ID: 9636566
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rejection episodes after liver transplantation during primary immunosuppression with FK506 or a cyclosporine-based regimen: a controlled, prospective, randomized trial.
    Jonas S; Kling N; Bechstein WO; Blumhardt G; Lohmann R; Lobeck H; Neuhaus P
    Clin Transplant; 1995 Oct; 9(5):406-14. PubMed ID: 8541635
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tacrolimus (FK506) proves superior to OKT3 for treating episodes of persistent rejection following intrathoracic transplantation.
    Meiser BM; Uberfuhr P; Schulze C; Fuchs A; Mair H; Reichenspurner H; Kreuzer E; Reichart B
    Transplant Proc; 1997; 29(1-2):605-6. PubMed ID: 9123150
    [No Abstract]   [Full Text] [Related]  

  • 28. Diabetes mellitus after renal transplantation under FK 506 (tacrolimus) as primary immunosuppression.
    Tanabe K; Koga S; Takahashi K; Sonda K; Tokumoto T; Babazono T; Yagisawa T; Toma H; Kawai T; Fuchinoue S; Teraoka S; Ota K
    Transplant Proc; 1996 Jun; 28(3):1304-5. PubMed ID: 8658670
    [No Abstract]   [Full Text] [Related]  

  • 29. Pharmacokinetics of tacrolimus: clinically relevant aspects.
    Undre NA; Stevenson P; Schäfer A
    Transplant Proc; 1999 Nov; 31(7A):21S-24S. PubMed ID: 10576037
    [No Abstract]   [Full Text] [Related]  

  • 30. Dose adjustment and cost of itraconazole prophylaxis in lung transplant recipients receiving cyclosporine and tacrolimus (FK 506).
    Kramer MR; Merin G; Rudis E; Bar I; Nesher T; Bublil M; Milgalter E
    Transplant Proc; 1997 Sep; 29(6):2657-9. PubMed ID: 9290780
    [No Abstract]   [Full Text] [Related]  

  • 31. Neoral is superior to FK 506 in liver transplantation.
    Levy GA
    Transplant Proc; 1998 Aug; 30(5):1812-5. PubMed ID: 9723293
    [No Abstract]   [Full Text] [Related]  

  • 32. Use of tacrolimus as the primary immunosuppression after renal transplant in Native Americans and Hispanics.
    Eghtesad B; Malhotra D; Hecker WP; Haq M; Gibel LJ; Wheeler D; Smith AY; Harford AM
    Transplant Proc; 1998 Jun; 30(4):1232-3. PubMed ID: 9636500
    [No Abstract]   [Full Text] [Related]  

  • 33. Review of transplantation--1999.
    Hirose R; Vincenti F
    Clin Transpl; 1999; ():295-315. PubMed ID: 11038649
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tacrolimus is effective in both dual and triple regimens after liver transplantation.
    Serrano J; García González M; Gómez M; Ortiz de Urbina J; López Cillero P; San Juan F; Parrilla P; Herrero JI
    Transplant Proc; 2002 Aug; 34(5):1529-30. PubMed ID: 12176469
    [No Abstract]   [Full Text] [Related]  

  • 35. Conversion of liver allograft recipients from cyclosporine A to FK 506 immunosuppressive therapy.
    Ben-Ari Z; Mor E; Shaharabani E; Bar-Nathan N; Shapira Z; Tur-Kaspa R
    Transplant Proc; 2000 Jun; 32(4):709-10. PubMed ID: 10856553
    [No Abstract]   [Full Text] [Related]  

  • 36. Mizoribine in combination therapy with tacrolimus for living donor renal transplantation: analysis of a nationwide study in Japan.
    Akiyama T; Okazaki H; Takahashi K; Hasegawa A; Tanabe K; Uchida K; Takahara S; Toma H
    Transplant Proc; 2005 Mar; 37(2):843-5. PubMed ID: 15848551
    [No Abstract]   [Full Text] [Related]  

  • 37. Tacrolimus and mycophenolate mofetil in cadaveric renal transplant recipients. The European Multicentre Tacrolimus/MMF Study Group.
    Forsythe J
    Transplant Proc; 1999 Nov; 31(7A):69S-71S. PubMed ID: 10576049
    [No Abstract]   [Full Text] [Related]  

  • 38. Immunosuppressive treatment after solid organ transplantation and risk of post-transplant cutaneous squamous cell carcinoma.
    Ingvar A; Smedby KE; Lindelöf B; Fernberg P; Bellocco R; Tufveson G; Höglund P; Adami J
    Nephrol Dial Transplant; 2010 Aug; 25(8):2764-71. PubMed ID: 19729465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic monitoring of tacrolimus in pediatric and adult transplanted patients.
    Capone D; Gentile A; Vajro P; Stanziale P; Imperatore P; De Silva C; Pellegrino T; Basile V
    J Chemother; 1998 Apr; 10(2):176-8. PubMed ID: 9603651
    [No Abstract]   [Full Text] [Related]  

  • 40. Evaluation of clinical and safety outcomes associated with conversion from brand-name to generic tacrolimus in transplant recipients enrolled in an integrated health care system.
    Spence MM; Nguyen LM; Hui RL; Chan J
    Pharmacotherapy; 2012 Nov; 32(11):981-7. PubMed ID: 23074134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.